Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AARTI DRUGS Plunges 4%; BSE HEALTHCARE Index Up 0.1%
Mon, 29 Jul 14:42

AARTI DRUGS Plunges 4%; BSE HEALTHCARE Index Up 0.1%Image source: CreativaImages/www.istockphoto.com

AARTI DRUGS share price has plunged 4% and is presently trading at Rs 506.0.

Meanwhile, the BSE HEALTHCARE index is at 40,224.5 (up 0.1%).

Among the top losers in the BSE HEALTHCARE index today are SUVEN PHARMACEUTICALS (down 3.6%) and Abbott India (down 2.2%).

FDC (up 5.8%) and ERIS LIFESCIENCES (up 2.8%) are among the top gainers today.

Over the last one year, AARTI DRUGS has moved down from Rs 608.5 to Rs 506.0, registering a loss of Rs 102.5 (down 16.8%).

On the other hand, the BSE HEALTHCARE index has moved up from 26,901.6 to 40,224.5, registering a gain of 49.5% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were Cadila Healthcare (up 99.2%), Lupin (up 98.2%) and Jubilant Pharmova (up 96.1%).

Dear Reader: If You Invest in Midcap Stocks, this is for You

What About the Benchmark Indices?

The BSE Sensex is at 81,328.5 .

The top losers among the BSE Sensex today are Titan (down 2.6%) and Bharti Airtel (down 2.0%). The most traded stocks in the BSE Sensex are Tata Steel and SBI.

In the meantime, NSE Nifty is at 24,831.2 . Titan and Bharti Airtel are among the top losers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 66,355.7 to 81,328.5, registering a gain of 14,972.8 points (up 22.6%).

AARTI DRUGS Financial Update...

AARTI DRUGS net profit fell 30.6% YoY to Rs 333 million for the quarter ended June 2024, compared to a profit of Rs 480 million a year ago. Net sales declined 16.0% to Rs 5,553 million during the period as against Rs 6,611 million in April-June 2023.

For the year ended March 2023, AARTI DRUGS reported 18.8% decrease in net profit to Rs 1,664 million compared to net profit of Rs 2,050 million during FY22. Revenue of the company grew 9.1% to Rs 27,161 million during FY23.

The current Price to earnings ratio of AARTI DRUGS, based on rolling 12 month earnings, stands at 29.7.


Equitymaster requests your view! Post a comment on "AARTI DRUGS Plunges 4%; BSE HEALTHCARE Index Up 0.1%". Click here!